AMAG Pharmaceuticals reviews Feraheme net product revenues of $13.

From December 31 Feraheme inventory amounts at wholesalers and distributors on a grams basis had been essentially unchanged, 2009 to March 31, 2010. AMAG estimates approximately 60 percent of Feraheme supplier demand in the first three months of 2010 was beyond the dialysis setting, with hospitals and hematology clinics representing the majority of this demand. Through the first 90 days of 2010, approximately 1,700 providers have purchased Feraheme, with higher than 67 percent having purchased on a do it again basis.This drug has the prospect of very serious side effects to all who consider it with the riskiest side effects being to those that may become pregnant. There are severe measures taken in order to avoid being pregnant while taking this drug and females of childbearing capabilities are carefully monitored through the entire duration of their treatment with this medication and for a brief period of time after the treatment ends. Beyond the risks of sever birth defects to unborn babies, medical risks to otherwise healthful adults can be quite severe.